Search Result

Results for "

Radiotracer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Linker (1) Adenosine Receptor (2) Amyloid-β (2) BCRP (1) Biochemical Assay Reagents (6) c-Fms (1) CD73 (1) CDK (1) CXCR (1) Dopamine Receptor (2) Drug Intermediate (1) Drug Metabolite (1) EGFR (3) FAP (11) Glycine Receptor (GlyR) (1) GPR39 (1) GSK-3 (2) HDAC (1) Integrin (3) LPL Receptor (1) mAChR (1) Microtubule/Tubulin (2) MMP (1) Opioid Receptor (2) P-glycoprotein (2) PD-1/PD-L1 (3) Phosphodiesterase (PDE) (3) Prolyl Endopeptidase (PREP) (1) PSMA (1) Radionuclide-Drug Conjugates (RDCs) (7) Reference Standards (3) Serotonin Transporter (1) Sigma Receptor (1) Tau Protein (2) Transmembrane Glycoprotein (1) Vasopressin Receptor (1) VEGFR (2) VISTA (1)
By Research Areas:	Cancer (33) Cardiovascular Disease (4) Inflammation/Immunology (5) Neurological Disease (19)

By Targets:

5-HT Receptor (1)

ADC Linker (1)

Adenosine Receptor (2)

Amyloid-β (2)

BCRP (1)

Biochemical Assay Reagents (6)

c-Fms (1)

CD73 (1)

CDK (1)

CXCR (1)

Dopamine Receptor (2)

Drug Intermediate (1)

Drug Metabolite (1)

EGFR (3)

FAP (11)

Glycine Receptor (GlyR) (1)

GPR39 (1)

GSK-3 (2)

HDAC (1)

Integrin (3)

LPL Receptor (1)

mAChR (1)

Microtubule/Tubulin (2)

MMP (1)

Opioid Receptor (2)

P-glycoprotein (2)

PD-1/PD-L1 (3)

Phosphodiesterase (PDE) (3)

Prolyl Endopeptidase (PREP) (1)

PSMA (1)

Radionuclide-Drug Conjugates (RDCs) (7)

Reference Standards (3)

Serotonin Transporter (1)

Sigma Receptor (1)

Tau Protein (2)

Transmembrane Glycoprotein (1)

Vasopressin Receptor (1)

VEGFR (2)

VISTA (1)

By Research Areas:

Cancer (33)

Cardiovascular Disease (4)

Inflammation/Immunology (5)

Neurological Disease (19)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128643

FAPI-4 Maximum Cited Publications 31 Publications Verification	FAP	Cancer
FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. ⁶⁸Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .

HY-137331

FAPI-46 2 Publications Verification	FAP	Cancer
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with ⁶⁸Ga or ¹⁷⁷Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .

HY-164316

FT-FAPI-12_9	FAP	Others
FT-FAPI-12_9 is a FAP ligand that can be used to synthesize FAPI-46, a radiotracer targeting FAP .

HY-153552A

NH2-UAMC1110 TFA	FAP	Cancer
NH2-UAMC1110 TFA is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 TFA is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose effect, and has been used in tumor diagnosis. NH2-UAMC1110 TFA structurally incorporates an active amino group, allowing it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.) to synthesize molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 TFA specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling-related processes. Its key activity is high targeting and high affinity, and its core function is to act as a targeting module coupled with bifunctional chelators (such as DOTA, DATA5m). NH2-UAMC1110 TFA can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .

HY-107531

A 1070722	GSK-3	Neurological Disease Cancer
A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective FAP inhibitor with an IC₅₀ value of 0.9 nM against FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-153248

PBR28	Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology
PBR28 is a translocator protein (TSPO) binding positron emission tomography (PET) radiotracer with blood-brain barrier permeability . PBR28 binds to TSPO, a marker of microglial activation and neuroinflammation, and is used for neuroinflammation imaging in brain diseases and HIV-infected individuals .

HY-135714

Bavarostat EKZ-001	HDAC Microtubule/Tubulin	Neurological Disease Cancer
Bavarostat (EKZ-001) is a blood-brain barrier-permeable, potent HDAC6 inhibitor and PET radiotracer, with an IC₅₀ as low as 17 nM against human HDAC6. Bavarostat can be labeled with ¹⁸F and used as a probe to map HDAC6 distribution and measure target occupancy in the brains of non-human primates. Bavarostat also selectively modulates tubulin acetylation, but not histone acetylation. Bavarostat is applicable for research on Alzheimer's disease, other neurodegenerative disorders, and cancers .

HY-153552

NH2-UAMC1110	FAP	Cancer
NH2-UAMC1110 is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose-response, and has been used for tumor diagnosis. NH2-UAMC1110 introduces an active amino group into its structure, enabling it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.), thereby synthesizing molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling processes. Its key activity is high targeting and high affinity, and its core function is to be coupled with bifunctional chelators (such as DOTA, DATA5m) as a targeting module. NH2-UAMC1110 can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .

HY-156991

NODAGA-NHS NODA-GA-NHS ester	EGFR Radionuclide-Drug Conjugates (RDCs)	Cancer
NODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate ⁶⁴Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [ ⁶⁴Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-100133A

DOTA-ADIBO TFA	Integrin	Cancer
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-101183

THK5351	Tau Protein	Neurological Disease
THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.

HY-135497

Fallypride	Dopamine Receptor	Neurological Disease
Fallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride ( ¹⁸F), can be used as a positron emission tomography (PET) radiotracer .

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linker Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-159108

AZ683	c-Fms	Cardiovascular Disease
AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (K_i=8 nM; IC₅₀=6 nM). AZ683 has good oral bioavailability. [ ¹¹C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) .

HY-106450

Binodenoson MRE-0470; WRC 0470	Adenosine Receptor	Cardiovascular Disease
Binodenoson (MRE-0470) is a potent and selective A2A adenosine receptor agonist (K_D=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging .

HY-100723

THK-523	Amyloid-β	Neurological Disease
THK-523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo. ¹⁸F-THK523 is a potent tau imaging radiotracer. ¹⁸F-THK523 is a potent in vivo tau imaging ligand for Alzheimer's disease .

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-129059

Odapipam 2 Publications Verification NNC 756	Dopamine Receptor	Neurological Disease
Odapipam (NNC 756) is a selective, high affinity and benzazepine dopamine D₁ receptor antagonist with a K_d of 0.18 nM. Odapipam is also a superior positron emission tomography (PET) radiotracer .

HY-175685

FAP-IN-7	FAP	Cancer
FAP-IN-7 (Compound 5b) is a FAPradiotracer for PET imaging and radionuclide therapy of cancers research .

HY-149860

FAP-IN-1	FAP	Cancer
FAP-IN-1 is a fibroblast activation protein (FAP) inhibitor with an IC₅₀ value of 3.3 nM. FAP-IN-1 can be used for the research of cancer .

HY-D2281

FAP Ligand 2	FAP	Cancer
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-W095635

Tetramethylammonium fluoride tetrahydrate	Biochemical Assay Reagents	Others
Tetramethylammonium fluoride tetrahydrate (TMAF) is a quaternary ammonium salt. TMAF is commonly used as a weak base and a source of fluoride ions in various organic reactions, including nucleophilic substitution, functional group deprotection, and ring-opening polymerization. Unlike other fluoride sources, TMAF is compatible with many functional groups, making it a versatile tool in synthetic chemistry. Functional reagents, In addition, TMAF has been used as a fluorinating agent in medicinal chemistry, for the preparation of radiotracers and protein modification in biochemistry, and the tetrahydrate form of TMAF is more stable and easier to handle than the anhydrous form.

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-171236

FEKAP	Opioid Receptor
FEKAP is a brain-penetrant and selective kappa opioid receptor (KOR) agonist (K_i = 0.43 nM) which isotope labeled form exhibits excellent imaging properties. ¹¹C-FEKAP can be utilized as a radiotracer for imaging KOR .

HY-P11025

TMVP1446	VEGFR	Cancer
TMVP1446 is a VEGFR-3 targeting peptide. TMVP1446 labeled with cyanine 7 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-175014

LGT-1	PD-1/PD-L1 Biochemical Assay Reagents	Cancer
LGT-1 is a PD-L1 ligand. LGT-1 labeled with ¹⁸F has an excellent specific uptake in B16-F10 tumor cells, and shows a high tumor uptake but a low liver uptake with good stability in B16-F10 tumor-bearing mice model. LGT-1 can be used as a radiotracer for PET imaging of PD-L1 expression in tumors .

HY-164316A

FT-FAPI-12_9 TFA	FAP	Cancer
FT-FAPI-12_9 TFA is a FAP ligand that can be used to synthesize FAPI-46, a radiotracer targeting FAP .

HY-145128

GR103545 fumarate	Opioid Receptor	Neurological Disease
GR103545 is a potent and selective agonist of the κ-opioid receptor (κ-OR). ¹¹GR103545 is a radiotracer for imaging κ-OR in vivo ^[1]

HY-159934

QI-18	FAP	Cancer
QI-18 is a fibroblast activation protein (FAP) inhibitor with the IC₅₀ of 0.50 nM, which is a 6.5-fold increase in potency over that of UAMC-1110 (HY-100684，IC₅₀ of 3.25 nM). QI-18 can be used to synthesize high tumor selectivity and high dose radiotracers for the diagnosis and study of tumors .

HY-P11088

VCAM1 binding peptide	Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
VCAM1 binding peptide is a VCAM1 binder with internalization activity. VCAM1 binding peptide can be labeled with 5-FAM. VCAM1 binding peptide serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide is applicable to studies related to atherosclerosis .

HY-206852

PF-06445974 precursor	Drug Intermediate Phosphodiesterase (PDE)	Neurological Disease
PF-06445974 precursor (Compound 28) is a nitro precursor and synthetic intermediate. PF-06445974 precursor can be used for the synthesis of PF-06445974 (HY-119190). PF-06445974 is a positron emission tomography (PET) compound that acts potently on PDE4B .

HY-P11253

DOTA-Bn-CA-170	VISTA	Inflammation/Immunology
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a K_d value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ ⁶⁸Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .

HY-W700684

N-Didesmethyl Loperamide R 21345	Drug Metabolite	Others
N-Didesmethyl Loperamide is a metabolite of Loperamide; a new and improved PET radiotracer for imaging P-gp function.

HY-124392

AMG580	Phosphodiesterase (PDE)	Cancer
AMG580 is a selective PDE10A antagonist with subnanomolar affinity for rat, primate, and human PDE10A. AMG580 can be used for the research of noninvasive radiotracer .

HY-D2310

CXCR2 Probe 1	CXCR	Inflammation/Immunology
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-146102

M1 ligand 1	mAChR	Others
M1 ligand 1 (compound 3b-b) is a muscarinic acetylcholine receptor M1 ligand. M1 ligand 1 is a N-desmethyl congener of arecoline derivative. M1 ligand 1 can be used as PET (positron emission tomography) radiotracer .

HY-D2311

CDK19 Probe 1	CDK	Cancer
CDK19 Probe 1 (Compound 10c) is a CDK19 inhibitor (IC₅₀: 1.01 μM) and can be used for cancer research .

HY-W792458

MADAM	Serotonin Transporter	Neurological Disease
MADAM exhibits high affinity and selectivity for 5-HTT with a K_i value of 1.6 nM. MADAM has the potential to serve as a PET radiotracer for visualizing the serotonin transporter .

HY-163327

pFBC	Biochemical Assay Reagents	Neurological Disease
pFBC ([ ¹⁸F]pEBC) is a covalent CLIP-tag radiotracer for detection of viral reporter gene transfer in the murine brain. pFBC can be used in neurobiological research .

HY-154868

MMP-13-IN-1	MMP	Cardiovascular Disease Cancer
MMP-13-IN-1 is a potent and selective inhibitor of MMP-13 with a IC₅₀ value of 16 nM. MMP-13-in-1 can be used for atherosclerosis research .

HY-171852

Iodoquine	Biochemical Assay Reagents	Cancer
Iodoquine is an analog of chloroquine. Iodoquine exhibits high uptake in tumor cells and can localize to cells with high ALDH1 content, including cancer stem cells. With low uptake in normal brain tissue, iodoquine can be used in research related to tumor diagnosis or as a radiotracer .

HY-163075

SYB4	Sigma Receptor	Others
SYB4 (compound 5) is a PET tracer which suitable for imaging the Sigma-2 Receptor in the brain of nonhuman primates .

HY-114253

ODS-2004436	EGFR	Cancer
ODS-2004436 is a small molecule radiotracer that uses positron emission tomography (PET) imaging to measure the activity of the epidermal growth factor receptor (EGFR) in tumors. ODS-2004436 labeled with the radioactive isotope fluorine-18 shows significantly higher uptake in the xenograft models of lung cancer with EGFR mutations compared to the wild-type models, and could be used to distinguish the mutation status. ODS-2004436 can be used to identify EGFR-positive tumors and predict their response to certain reagent treatments, especially for non-small cell lung cancer (NSCLC) .

HY-106450R

Binodenoson (Standard) MRE-0470 (Standard); WRC 0470 (Standard)	Reference Standards Adenosine Receptor	Cardiovascular Disease
Binodenoson (Standard) is the analytical standard of Binodenoson (HY-106450). This product is intended for research and analytical applications. Binodenoson (MRE-0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging .

HY-180526

PDE2A-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE2A-IN-2 is a selective and brain-penetrant PDE2A inhibitor (K_i = 5.49 nM and 100 > fold selectivity over other PDE isoforms). The ¹¹C-labeled PDE2A-IN-2 serves as a positron emission tomography (PET) tracer for brain imaging in patients with neurodegenerative diseases. PDE2A-IN-2 educes the radiotracer signal in PDE2A-rich regions in vitro. PDE2A-IN-2 exhibits low binding affinity in vivo. PDE2A-IN-2 can be used for neurodegenerative diseases .

HY-181919

CD73-IN-22	CD73 Radionuclide-Drug Conjugates (RDCs)	Cancer
CD73-IN-22 (Compound HX-6) is a non-nucleoside CD73 inhibitor with an IC₅₀ of 0.07 μM. When radiolabeled with ⁶⁸Ga, CD73-IN-22 acts as a PET radiotracer for detecting CD73 expression. When radiolabeled with ¹⁷⁷Lu, CD73-IN-22 exhibits anticancer activity against colorectal adenocarcinoma. CD73-IN-22 is applicable to research related to colon adenocarcinoma and breast cancer .

HY-149219

BIBD-124	Amyloid-β	Neurological Disease
BIBD-124 binds amyloid beta (Aβ) plaque with an IC₅₀ value of 9.51 nM. [18F]BIBD-124 can be used as radiotracer of Aβ plaques .

HY-182626

CS1P1	LPL Receptor	Others Neurological Disease Inflammation/Immunology
CS1P1 is a brain-penetrant and selective S1PR1 antagonist and PET radiotracer, with human S1PR1 IC₅₀ values of 2.1 nM. CS1P1 binds specifically to S1PR1 to enable in vivo receptor expression quantification. CS1P1 can be used as PET radiotracer when labelled with 11C. CS1P1 can be used for the research of multiple sclerosis, neointimal hyperplasia, vascular inflammation .

Cat. No.	Product Name	Type

HY-D2281

FAP Ligand 2	Fluorescent Dyes
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-D2310

CXCR2 Probe 1	Fluorescent Dyes
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-D2311

CDK19 Probe 1	Fluorescent Dyes
CDK19 Probe 1 (Compound 10c) is a CDK19 inhibitor (IC₅₀: 1.01 μM) and can be used for cancer research .

Cat. No.	Product Name	Type

HY-100133A

DOTA-ADIBO TFA	Biochemical Assay Reagents
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-101183

THK5351	Biochemical Assay Reagents
THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.

HY-W095635

Tetramethylammonium fluoride tetrahydrate

Biochemical Assay Reagents

Tetramethylammonium fluoride tetrahydrate (TMAF) is a quaternary ammonium salt. TMAF is commonly used as a weak base and a source of fluoride ions in various organic reactions, including nucleophilic substitution, functional group deprotection, and ring-opening polymerization. Unlike other fluoride sources, TMAF is compatible with many functional groups, making it a versatile tool in synthetic chemistry. Functional reagents, In addition, TMAF has been used as a fluorinating agent in medicinal chemistry, for the preparation of radiotracers and protein modification in biochemistry, and the tetrahydrate form of TMAF is more stable and easier to handle than the anhydrous form.

HY-101183R

THK5351 (Standard)	Biochemical Assay Reagents
THK5351 (Standard) is the analytical standard of THK5351 (HY-101183). This product is intended for research and analytical applications. THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.

Cat. No.	Product Name	Target	Research Area

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective FAP inhibitor with an IC₅₀ value of 0.9 nM against FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-P10734

NODAGA-RGD	Peptides
NODAGA-RGD is a peptide that can be radiolabeled and used as a radiotracer for positron emission tomography (PET) diagnosis .

HY-P11318

NOTA-NOC	Peptides	Cancer
NOTA-NOC is a peptide conjugated to a radiotracer, such as gallium-68 or fluorine-18, for use in PET/CT scans to diagnose and monitor neuroendocrine tumors .

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-P11025

TMVP1446	VEGFR	Cancer
TMVP1446 is a VEGFR-3 targeting peptide. TMVP1446 labeled with cyanine 7 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-P11088

VCAM1 binding peptide	Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
VCAM1 binding peptide is a VCAM1 binder with internalization activity. VCAM1 binding peptide can be labeled with 5-FAM. VCAM1 binding peptide serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide is applicable to studies related to atherosclerosis .

HY-P11253

DOTA-Bn-CA-170	VISTA	Inflammation/Immunology
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a K_d value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ ⁶⁸Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

HY-P11598

PSMA-N5	PSMA	Cancer
PSMA-N5 (Compound 15) is a PSMA ligand with a K_i value of 0.71 nM. PSMA-N5 acts as a PET radiotracer for prostate cancer imaging. PSMA-N5 is applicable to the research of prostate cancer and other related cancers .

HY-P11774

HYNIC-3P-RGD2	Integrin	Cancer
HYNIC-3P-RGD2 is a dimeric cyclic RGD peptide with high binding affinity for integrin α_vβ₃ (IC₅₀ = 33 nM). HYNIC-3P-RGD2 acts as a precursor molecule for radiotracers and is used to detect tumor angiogenesis .

HY-P11773

3P-RGD2	Radionuclide-Drug Conjugates (RDCs) Integrin	Others
3P-RGD2 is a dimeric cyclic RGD (Arg-Gly-Asp) peptide. When radiolabeled with ^99mTc, 3P-RGD2 serves as a selective radiotracer for integrin α_vβ₃. When radiolabeled with ^99mTc, 3P-RGD2 enables single-photon emission computed tomography imaging of integrin α_vβ₃ .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992475

Tecnemab K1	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: